EarningsScheduled · Nov 12, 2026
Onconetix reports Nov 12.
The date the company scheduled. A company can move it.
Last report: Q2 FY2026, Aug 13, 2026. In line on revenue.
Every quarter
Congress trades
Biotechnology, listed on NASDAQ.
20 Congress trades · last filed Nov 10, 2025
EarningsScheduled · Nov 12, 2026
Onconetix reports Nov 12.
The date the company scheduled. A company can move it.
Last report: Q2 FY2026, Aug 13, 2026. In line on revenue.
Every quarterCongressSTOCK Act disclosures to the House and Senate
19 Congress disclosures shown, from 4 members.
| Quarter | EPS | EPS expected | Revenue | Revenue expected | Result |
|---|---|---|---|---|---|
| Q2 FY2026reported Aug 13, 2026 | -$1.28 | n/a | $17K | $17K | EPS n/aRevenue in line |
| Q1 FY2026reported May 13, 2026 | -$67.10 | n/a | $21K | n/a | EPS n/aRevenue n/a |
| Q4 FY2025reported Mar 13, 2026 | $10.40 | n/a | $304K | n/a | EPS n/aRevenue n/a |
| Q3 FY2025reported Nov 13, 2025 | -$312.50 | n/a | $304K | n/a | EPS n/aRevenue n/a |
| Q2 FY2025reported Aug 14, 2025 | -$202.50 | n/a | $106K | n/a | EPS n/aRevenue n/a |
| Q1 FY2025reported Jun 12, 2025 | -$1059.32 | n/a | $102K | n/a | EPS n/aRevenue n/a |
Actual against the consensus estimate at the time. A flag marks a beat or a miss of more than 1.5% either way; inside that band the quarter is in line. A figure or flag reads n/a when a number is missing, or when the figure failed our check against the company's other quarters, its own filings and its share splits, and was left out. Quarterly EPS is the figure set against the consensus, usually adjusted, so the quarters need not add up to the 12-month net income per share above. An estimate is a forecast made by analysts, not a company target.
Since the trade: the stock's move from its estimated entry price (a purchase) or estimated exit price (a sale) to its current price, the latest close we hold. Not the member's result.
| Member | Type | Action | Amount disclosed | Since the trade | Trade date | Disclosed | Delay |
|---|---|---|---|---|---|---|---|
| Stock | Sale | $1,001 - $15,000 | n/a | Oct 17, 2025 | Nov 10, 2025 | 24d | |
| Stock | Purchase | $1,001 - $15,000 | n/a | Oct 11, 2023 | Nov 13, 2023 | 33d | |
| Stock | Sale | $100,001 - $250,000 | n/a | Aug 24, 2023 | Sep 14, 2023 | 21d | |
| Stock | Purchase | $100,001 - $250,000 | n/a | Jul 14, 2023 | Aug 16, 2023 | 33d | |
| Stock | Purchase | $100,001 - $250,000 | n/a | Apr 18, 2023 | May 12, 2023 | 24d | |
| Stock | Purchase | $1,001 - $15,000 | n/a | Apr 10, 2023 | May 9, 2023 | 29d | |
| Stock | Purchase | $1,001 - $15,000 | n/a | Mar 14, 2023 | Apr 7, 2023 | 24d | |
| Stock | Purchase | $100,001 - $250,000 | n/a | Jan 3, 2023 | Feb 15, 2023 | 43d | |
| Stock | Purchase | $1,001 - $15,000 | n/a | Sep 29, 2022 | Oct 7, 2022 | 8d | |
| Stock | Purchase | $1,001 - $15,000 | n/a | Jun 27, 2022 | Jul 7, 2022 | 10d | |
| Bond | Sale | $15,001 - $50,000 | n/a | Jun 30, 2022 | Jul 7, 2022 | 7d | |
| Stock | Purchase | $1,001 - $15,000 | n/a | May 16, 2022 | May 26, 2022 | 10d | |
| Stock | Purchase | $100,001 - $250,000 | n/a | Jan 26, 2022 | Feb 23, 2022 | 28d | |
| Bond | Purchase | $1,001 - $15,000 | n/a | Jan 22, 2019 | Feb 25, 2019 | 34d | |
| Stock | Sale | $15,001 - $50,000 | n/a | Oct 24, 2018 | Nov 15, 2018 | 22d | |
| Bond | Purchase | $100,001 - $250,000 | n/a | Aug 28, 2018 | Sep 12, 2018 | 15d | |
| Bond | Purchase | $100,001 - $250,000 | n/a | Sep 6, 2018 | Sep 12, 2018 | 6d | |
| Stock | Sale | $1,001 - $15,000 | n/a | Dec 9, 2015 | Feb 3, 2016 | 56d | |
| Stock | Sale | $1,001 - $15,000 | n/a | Mar 6, 2014 | Apr 10, 2014 | 35d |
We hold no closing prices for any row shown here, so no move is shown. Not investment advice.
Estimated prices are the stock's closing price on the trade date. A disclosure gives a value band, not the price paid. Not investment advice. After a sale a positive figure means the stock kept rising after it. On an option line the prices are the stock's, never the option's: the premium is never disclosed.
A delay above 45 days is the gap between the dates on the report; we mark a filing late only after checking it.
"Not captured" means the band or the transaction type on the original report is missing from our data.
"Dates conflict" marks a row whose disclosure is dated before its trade on the record we hold. Both dates are printed as filed, and no prices or move are shown for that row.
Every Congress trade in ONCO filterable by party, chamber, type and account.
Congress rows disclose a value range rather than an exact amount, and the STOCK Act allows up to 45 days to report. Full sourcing and the limits of this data are on the methodology page. A filing is a record of a transaction, not a signal, and nothing here is investment advice.
A STOCK Act disclosure gives each trade as a band of dollar values, which we do not narrow, and is due within 45 days of the trade. An option is described by its underlying company's name; its row says it is an option.
Data as of Nov 9, 2026.
What the filings on ONCO show and how current they are.
Michael T. McCaul, Charles J. "Chuck" Fleischmann, Ro Khanna and Diana Harshbarger disclosed ONCO transactions in the filings shown here.
Congressional disclosures took a median of 24 days, against the 45 the STOCK Act allows.